Contineum Therapeutics, Inc. Operating Cash Flow
Contineum Therapeutics, Inc. (CTNM) reported Operating Cash Flow of -$27.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$11.50M.
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$16.27M.
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$13.04M.
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$12.20M.
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$55.31M.
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$32.84M, a 269.75% decline from fiscal 2023.
- Contineum Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $19.35M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$27.77M 10-Q · filed 2026-07-30 | -$40.81M derived: sum of 3 quarters · filed 2026-07-30 | -$53.01M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$16.27M 10-Q · filed 2026-05-05 | -$29.31M derived: sum of 2 quarters · filed 2026-05-05 | -$41.51M derived: sum of 3 quarters · filed 2026-05-05 | -$57.17M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$13.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$25.24M derived: sum of 2 quarters · filed 2026-03-05 | -$40.90M derived: sum of 3 quarters · filed 2026-07-30 | -$55.31M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$12.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$27.86M derived: sum of 2 quarters · filed 2026-07-30 | -$42.27M 10-Q · filed 2025-10-30 | -$52.47M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$15.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$30.07M 10-Q · filed 2026-07-30 | -$40.27M derived: sum of 3 quarters · filed 2026-07-30 | -$46.44M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$14.41M 10-Q · filed 2026-05-05 | -$24.61M derived: sum of 2 quarters · filed 2026-05-05 | -$30.78M derived: sum of 3 quarters · filed 2026-05-05 | -$39.28M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$16.37M derived: sum of 2 quarters · filed 2026-03-05 | -$24.87M derived: sum of 3 quarters · filed 2026-03-05 | -$32.84M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$6.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$14.67M derived: sum of 2 quarters · filed 2025-10-30 | -$22.64M 10-Q · filed 2025-10-30 | -$33.35M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$16.47M 10-Q · filed 2025-08-05 | -$27.18M derived: sum of 3 quarters · filed 2025-08-05 | -$32.55M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$7.97M 10-Q · filed 2025-05-14 | -$18.68M derived: sum of 2 quarters · filed 2025-05-14 | -$24.06M derived: sum of 3 quarters · filed 2025-05-14 | $16.62M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$16.08M derived: sum of 2 quarters · filed 2025-03-06 | $24.59M derived: sum of 3 quarters · filed 2025-03-06 | $19.35M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$5.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $35.30M derived: sum of 2 quarters · filed 2024-11-06 | $30.05M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $40.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $35.43M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$5.24M 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |